Genenta secures €20 million for cancer research expansion

Genenta Science, a biotech company focused on cancer treatments, has announced a new funding of €20 million (about $21.9 million). This financing, from ENEA Tech and Biomedical, will help Genenta expand its research and development efforts. The funds will primarily be used to support the development of Genenta's therapy, Temferon, which is currently being tested on patients with metastatic Renal Cell Carcinoma. ENEA Tech is a recognized foundation in Italy, managing a large portfolio of biotech investments. Recently, Genenta reported encouraging results from its Phase 1/2a trial for patients with Glioblastoma Multiforme. The trial showed that the survival rate for these patients at two years increased to 29%, up from 25% last October. Additionally, the median overall survival for patients has increased to 17 months. As Genenta continues its clinical studies, they are optimistic about advancing Temferon further in treating other types of cancer. The company aims to enhance the effectiveness of existing cancer treatments by combining their therapies with immune checkpoint inhibitors. While these updates are promising, Genenta reminds investors that clinical trials involve risks and uncertainties, which can affect outcomes. The details of the new financing and clinical trials can be found in their official filings.